Literature DB >> 7237786

Further studies on plasma proteins, lipids, and dye- and drug-binding in a child with analbuminemia.

J Frohlich, M R Pudek, E J Cormode, E M Sellers, J G Abel.   

Abstract

A previously reported patient with analbuminemia was re-investigated after 4 1/2 years, at age 6. The serum albumin concentration was 150 mg/L by radioimmunoassay. Most of the observed increase in total plasma protein over the 4 1/2 years was attributable to gamma-globulin. Concentrations of total and high-density lipoprotein cholesterol were increased; the esterified:free ratio and the lecithin-cholesterol acyltransferase activity were both normal. Albumin is apparently not essential for binding of lysolecithin generated by the acyltransferase-catalyzed reaction. The binding of bromphenol blue suggested that analbuminemic serum has about 25% of normal binding capacity for bilirubin (more than expected in a patient with analbuminemia), which may explain why newborns with this disorder do not develop kernicterus. Binding by the patient's plasma of diazepam (1020 mg/L) and warfarin (1040 mg/L), which bind primarily to albumin, as well as of propranolol (1.05 g/L), which binds primarily to alpha 1-acid glycoprotein, was also studied. The proportions of free diazepam (14.4%) and warfarin (4.8%) were about 10-fold normal. In contrast, the proportion of propranolol in the free form was decreased (4.5%). Evidently, other plasma proteins are partly compensating for the deficiency of albumin.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7237786

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  11 in total

Review 1.  Congenital analbuminaemia: biochemical and clinical implications. A case report and literature review.

Authors:  Bart G P Koot; Roderick Houwen; Dirk-Jan Pot; Jeroen Nauta
Journal:  Eur J Pediatr       Date:  2004-08-06       Impact factor: 3.183

2.  Pregnancy in a patient with congenital analbuminaemia.

Authors:  Hillary Hu; Roshini Nayyar; Lucinda Jean Berglund; Elizabeth Anne Anderson
Journal:  BMJ Case Rep       Date:  2017-02-02

3.  Analbuminaemia: a natural model of metabolic compensatory systems.

Authors:  G Baldo-Enzi; M R Baiocchi; G Vigna; C Andrian; C Mosconi; R Fellin
Journal:  J Inherit Metab Dis       Date:  1987       Impact factor: 4.982

4.  A nucleotide insertion and frameshift cause analbuminemia in an Italian family.

Authors:  S Watkins; J Madison; M Galliano; L Minchiotti; F W Putnam
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

5.  Clinical chemistry of human FcRn transgenic mice.

Authors:  Carsten Stein; Lothar Kling; Gabriele Proetzel; Derry C Roopenian; Martin Hrabě de Angelis; Eckhard Wolf; Birgit Rathkolb
Journal:  Mamm Genome       Date:  2011-12-23       Impact factor: 2.957

6.  Divergent effects of raloxifene HCI on the pharmacokinetics and pharmacodynamics of warfarin.

Authors:  J W Miller; A Skerjanec; M P Knadler; A Ghosh; S R Allerheiligen
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

7.  Coronary artery bypass surgery in a patient with analbuminemia.

Authors:  Ergun Demirsoy; Gokce Sirin; Emre Ozker
Journal:  Tex Heart Inst J       Date:  2011

8.  Changes of lidocaine levels in rat serum and tissue under stress and hyperlipidaemic diets.

Authors:  Dimitrios Karakitsos; Andreas Karabinis; Antonia Kotsiou
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Jul-Sep       Impact factor: 2.441

9.  Analbuminemia: three cases resulting from different point mutations in the albumin gene.

Authors:  S Watkins; J Madison; M Galliano; L Minchiotti; F W Putnam
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

10.  Analbuminemia.

Authors:  E Russi; K Weigand
Journal:  Klin Wochenschr       Date:  1983-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.